<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370460</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 6669</org_study_id>
    <nct_id>NCT01370460</nct_id>
  </id_info>
  <brief_title>Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty</brief_title>
  <official_title>Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess postoperative blood loss and transfusion rates in total knee
      replacement after one-time administration of topical tranexamic acid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autologous (donor) blood transfusion is an expensive and common occurrence after total knee
      replacement. Published data puts this rate between 9 and 40% after primary unilateral total
      knee arthroplasty. There have been many proposed adjunctive measures to decrease
      intraoperative and postoperative blood loss during such surgery. Most of these include
      thrombin inhibition, so-called &quot;minimally- invasive&quot; techniques or instrumentation, or other
      adjunctive drugs. Hitherto, tranexamic acid, a specific drug that promotes part of the
      clotting cascade, has been used extensively in multiple areas of surgery with multiple
      studies evaluating its efficacy in cardiac surgery, spinal procedures, and as a dental
      swishing solution after tooth extraction. There have been small studies evaluating
      intravenous tranexamic acid and its effect on total knee replacement, with some promising
      results. The topical form of TA has been evaluated in only one prospective, randomized
      clinical trial with a significant decrease in postoperative blood loss and a trend towards
      decreased autologous blood transfusion rates. This study proposes to further evaluate
      tranexamic acid as an inexpensive and viable option for use in total knee arthroplasty. The
      topical form of the drug has been shown to achieve these hemostatic effects without
      increasing the risk of blood clots after surgery. Furthermore, the one aforementioned
      randomized clinical trial used a variety of postoperative deep vein thrombosis prophylaxis
      after surgery and introduced a potential confounding variable. A rigorous analysis of the
      effects of tranexamic acid demand a more standardized approach. Such a regimen is practiced
      at Henry Ford Hospital as all patients on the Adult Reconstruction service are placed on an
      identical dose of enoxaparin (a subcutaneous blood thinner) postoperatively for two weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Loss</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 3 days</time_frame>
    <description>Preoperative and lowest postoperative hemoglobin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Transfusion Rate</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 3 days</time_frame>
    <description>Number of patients with symptomatic (tachycardia, hypotension, presyncope) anemia of &lt; 8.0g/dL hemoglobin, or any hemoglobin &lt;7.0 g/dL, precipitated transfusion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Acute Blood Loss Anemia</condition>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical tranexamic acid (2g/100mL) applied during unilateral total knee arthroplasty.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100mL 0.9% NS, applied topically</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Topical tranexamic acid (2g/100mL 0.9% saline)</description>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100mL 0.9% sterile saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adult patients over age eighteen

          -  Primary unilateral total knee arthroplasty at Henry Ford Hospital (Detroit, Michigan,
             United States) and Henry Ford West Bloomfield Hospital (West Bloomfield, Michigan,
             United States)

        Exclusion Criteria:

          -  patient history of venous thromboembolic disease or coagulopathy

          -  use of anticoagulant medications within 7 days of surgery

          -  history of arterial embolic disease

          -  history of Class III or IV heart failure

          -  renal failure

          -  intraoperative cardiovascular, pulmonary, orthopaedic, or anesthetic complication (MI,
             intraoperative fracture, vasopressor support, emergent intubation).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Laker, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962 Feb;51(2):224-32.</citation>
    <PMID>21936146</PMID>
  </reference>
  <reference>
    <citation>Good L, Peterson E, Lisander B. Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement. Br J Anaesth. 2003 May;90(5):596-9.</citation>
    <PMID>12697586</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2011</study_first_submitted>
  <study_first_submitted_qc>June 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2011</study_first_posted>
  <results_first_submitted>March 27, 2013</results_first_submitted>
  <results_first_submitted_qc>July 3, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 9, 2013</results_first_posted>
  <last_update_submitted>July 3, 2013</last_update_submitted>
  <last_update_submitted_qc>July 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Michael Laker</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Tranexamic Acid</keyword>
  <keyword>Blood transfusion</keyword>
  <keyword>Total knee arthroplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>We planned on 50 patients per treatment arm (100 patients total) and ended up with 101 patients total. We naturally wished to recruit more than the minimum to avoid the risk of jeopardizing statistical significance. There is no discrepancy that needs to be reconciled, except perhaps this explanation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tranexamic Acid</title>
          <description>Topical tranexamic acid (2g/100mL) applied during unilateral total knee arthroplasty.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>100mL 0.9% NS, applied topically</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tranexamic Acid</title>
          <description>Topical tranexamic acid (2g/100mL) applied during unilateral total knee arthroplasty.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>100mL 0.9% NS, applied topically</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="9"/>
                    <measurement group_id="B2" value="64.5" spread="8.2"/>
                    <measurement group_id="B3" value="65.75" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Blood Loss</title>
        <description>Preoperative and lowest postoperative hemoglobin</description>
        <time_frame>participants will be followed for the duration of hospital stay, an expected average of 3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>100mL 0.9% NS, applied topically</description>
          </group>
          <group group_id="O2">
            <title>Tranexamic Acid</title>
            <description>Topical tranexamic acid (2g/100mL) applied during unilateral total knee arthroplasty.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Loss</title>
          <description>Preoperative and lowest postoperative hemoglobin</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1293.1" spread="532.7"/>
                    <measurement group_id="O2" value="940.2" spread="327.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Transfusion Rate</title>
        <description>Number of patients with symptomatic (tachycardia, hypotension, presyncope) anemia of &lt; 8.0g/dL hemoglobin, or any hemoglobin &lt;7.0 g/dL, precipitated transfusion.</description>
        <time_frame>participants will be followed for the duration of hospital stay, an expected average of 3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid</title>
            <description>Topical tranexamic acid (2g/100mL) applied during unilateral total knee arthroplasty.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>100mL 0.9% NS, applied topically</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Transfusion Rate</title>
          <description>Number of patients with symptomatic (tachycardia, hypotension, presyncope) anemia of &lt; 8.0g/dL hemoglobin, or any hemoglobin &lt;7.0 g/dL, precipitated transfusion.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Adverse Events Not Collected</title>
          <description>Adverse Events Not Collected</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Blood loss was calculated taking change in hemoglobin as described (units g/dL) and converting to blood loss (mL) according to the formulas includes in the papers cited in this entry (Good 2003 Br J Anesthesia; Nadler 1962 Surgery).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Andrew Georgiadis, MD</name_or_title>
      <organization>Henry Ford Health System</organization>
      <phone>313-916-7520</phone>
      <email>ageorgi1@hfhs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

